

## ACRYLAMIDE TOXICITY

P. Sobotka

Department of pathophysiology, Medical Faculty, Charles University, Pilsen

The mankind in the contact with the external environment is all the time exposed to huge amount of different pollutions. Conventionally it concerns atmosphere, watercourses, land, industries and foodstuffs. In the last years attention was devoted to the toxic action of acrylamide. As an important industrial chemical acrylamide (AA) and its polymers are used for flocculants of waste waters, production of paper and pulp and for preparation of gels applied in chromatography and electrophoresis.

Acrylamide  $C_3H_5NO$  (CAS No 79-06-01) is a colorless and odorless crystalline solid soluble in water. As a monomer it is formed in heated starchy food as a result of Maillard reaction (40, 48). AA is a type – 2 alkene a chemical class that includes structurally related electrophilic environmental pollutants and endogenous mediators of cellular oxidative stress (35). Chromatographic methods enable fast, accurate and reproducible determination of AA (3, 52). AA is metabolized primarily to glycidamide. It also undergoes detoxification by conjugation with glutathione (34). Decomposition products of AA may participate on its toxicity (27, 29, 51). There were assest values of  $LD_{50}$  of AA and its derivatives in experimental animals (70). Hemoglobine adducts of AA and glycidamide have been measured as a biomarkers of AA exposure in a represenatative sample of the USA population. Smoking was significantly correlated with these adducts (4, 69). AA is present in commonly used foods (31). Amount of AA in different products are published (34, 48). AA content in dry foodstuffs for dog and cat are also determined (68). Dietary intake of AA differs greatly among European adults residing in different geographical regions (18). Poland young population consumes the highest amount of AA (73). Specially the AA content in baby food products is even dozen times higher than the exposure estimated for the total Polish population (40).

Neurotoxic effects of AA were proven in laboratory animals *in vivo* and *in vitro*. They involve the peripheral and the central nervous system by the damage of the nerve ternimals through membrane fusion mechanisms and tubulovesicular alterations. Changes in neural specific mRNA<sub>s</sub> are sensitive to neurotoxic damage (67). In cultured fibroblast cell lines AA is responsible for neurite disintegration (71). Similar effects are with rat dorsal root ganglia (63). There are alterations in the axonal transport of proteins, glycoproteins and

gangliosides in sensory neurons of rat sciatic nerve (24), inhibition of creatine kinase from brain or sciatic nerve (37). Reduction of protein delivery contributes to axonal degeneration (57). Progressive deficits in retrograde axon transport precede degeneration of motor axons (41). There are extensive pathological changes at the neuromuscular junctions (13) and heterogeneous visceral nerve changes (17). Axonal atrophy can mask the development of neurofilamentous axonal swelling (21). The incubation of AA with rat brain homogenates was followed by a decrease in catalase activity (65). Changes in the phosphorylation of phospholipids and protein in the nerves are the component of AA neurotoxic mechanism (5). Voltage clamp and electronmicroscopic analysis of rat sciatic nerve confirmed distal axon degeneration (8). Well documented is neurotoxic effect due to cerebellar Purkinje cell damage and central-peripheral distal axonopathy. In rats the damage of far-field somatosensory evoked potentials may occur through the system including the spinal cord, dorsal column nuclei, medial lemniscus, thalamus and sensory radiation (7). Neuropathy involving sensitive nerves of the rat urinary bladder leads to severe urinary retention (1). Neuropathy in dogs abolished the cough reflex (25). In cats were described spinal cord defects and peripheral neuropathy (22), in monkeys loss of vibration sensitivity (38), loss of regulation in axoplasm of myelinated rat tibial nerve fibers (35). There is also inhibition of rat mitochondrial energy production (39). Russom et al. (53) describe acute toxicity and behavioral effects of acrylates in juvenile fathead minnows.

AA produces developmental and postnatal effects in mouse and rat offsprings following administration to pregnant dams. It also produces neurotoxic effects in the neonates at levels that are not toxic to the dam. Chromosomal changes indicate its clastogenic potential and genotoxic effects (9, 11). Lower fertilizing ability of the sperm plays a major role in the reduced reproductive competence in rats (62). The same effect has in mice the decrease sperm count and abnormal sperm morphology (55). Mammalian spot test revealed mutagenic and teratogenic effects (42).

Animal experiments provide evidence that AA induces not only mutagenicity but especially mammary gland tumors in female rats (35). Many other tumors were observed, e. g. adenocarcinoma of different organs, papilloma and carcinoma of oral cavity, mesothelioma, pituitary adenoma and adenocarcinoma (12). In a chronic study with AA in drinking water various tumors were found as astrocytoma, oligodendroglioma of the brain, pheochromocytoma of the adrenal gland, malignant leukemia (26) and aberrations in the bone marrow (11). In the contact with the skin AA produces in mice irritation, scabbing, hyperkeratosis, papillomas, carcinomas and melanomas (72).

The consequences of AA contact in human are not uniform. Association between chemical exposure and self-reported symptoms should be interpreted with great caution, because in tunnel workers previously exposed to grout containing AA there were not found health outcomes as measured by the chosen neuropsychological tests (20). Contrary occupational health hazard in professional exposition to AA is generally accepted (19). For the most part there are described variable objective unfavourable consequences. Prevail peripheral neuropathies with paresthesia, pain, cramps, attacks of white fingers, hands and

feet accompanied with sweating, numbness and fatigue (50), neurovegetative and neurotic disturbances (30), emesis and diarrhea (70). Often occur allergic contact dermatoses and occupational asthma (28) connected with generalized urticaria in laboratory workers. There are also midbrain, cerebellar and optic nerve alterations. EEG changes were described in workers exposed to AA in laboratory and semibusiness conditions (55). Due to nerve terminal damage AA may contribute to the development of Alzheimer disease (51). Exposure to acrylnitrile was followed by accumulation of acrylate adducts with erythrocytic hemoglobin (4, 65). In a prospective European mother-child study both AA and glycidamide hemoglobin adducts were associated with significant lowering in birth weight and head circumference. Thus dietary intake of AA should be reduced among pregnant women (46). Also the Norwegian mother and child cohort study proved that AA intake during pregnancy was negatively associated with fetal growth (15).

In human there is lack of an increased risk of most types of cancers from exposure to AA. The main association that requires further monitoring involves kidney cancer (49). In a prospective study from 10 European countries the dietary intake of AA was not associated with an increased risk of the pancreas adenocarcinoma (44). Also no association was observed between AA intake and endometrial cancer. However a positive association with type I was observed in women who were nonusers of oral contraceptives and never smokers (43). A cohort of 2293 men from the USA and the Netherlands exposed to AA showed no trend of increased risk of mortality from several cancer sites (10). The mortality of 371 employees did not support a cause effect relation between exposure to AA and overall mortality, total malignant neoplasms or any specific cancers (58). Contrary in a Danish cohort of postmenopausal women the prediagnostic exposure to AA was related to mortality of endocrine related types of breast cancer patients (45).

There are efforts to elaborate strategies for mitigation of unfavourable effects of AA. Preventive measures are based on the use of the asparaginase and thermal input reduction and vacuum treatment aimed to remove the already formed AA from the product (2). There are procedures to reduce AA in the main foods (48). Some dietary components as tea polyphenols in green tea, resveratrol in grapes, diallyltrisulfide in garlic, flavonoids in citrus and tomato are able to ameliorate AA toxicity (51). The negative impact of AA on structure and innervation of the small intestine wall in mice can be abolished by dietary potato fiber preparations (14). Selenium dietary supplement can prevent the biochemical changes in the liver in rats (66). Fish oil has a neuroprotective effect on the AA induced neurotoxicity in rats (32). Treatment with gangliosides stimulates the regenerative potential of AA damaged nerves (61). ACTH and related peptides improve recovery from neuropathy in rats (60).

## SUMMARY

In a review there are described toxic consequences of acrylates in animal experiments, and in man in industry business, in laboratories and in foodstuffs.

## *Toxicita akrylamidu*

SOUHRN

V přehledu jsou popsány toxické účinky akrylátů v pokusech na zvířatech a u lidí v průmyslových provozech, v laboratořích a v potravinách.

### REFERENCES

1. Abelli L., Ferri G. L., Astolfi M. et al.: Acrylamide-induced visceral neuropathy. Evidence for the involvement of capsaicin-sensitive nerves of the rat urinary bladder. *Neurosci.* 41, 1991: 311–21. – 2. Anese M., Manzocco L., Calligaris S. et al.: Industrially applicable strategies for mitigating acrylamide, furan and 5-hydroxymethylfurfural in food. *J. Agric. Food Chem.* 61, 2013: 10209–14. – 3. Arvanitoyannis I. S., Dionisopulu N.: Acrylamide: formation, occurrence in food products, detection methods, and legislation. *Crit. Rev. Food Sci. Nutr.* 54, 2014: 708–33. – 4. Bergmark E., Calleman C. J., Costa L. G.: Formation of hemoglobin adducts of acrylamide and its epoxide metabolite glycidamide in the rat. *Toxicol. appl. Pharmacol.* 111, 1991: 352–63. – 5. Berti-Mattera L. N., Eichberg J., Schrama L. et al.: Acrylamide administration alters protein phosphorylation and phospholipid metabolism in rat sciatic nerve. *Toxicol. appl. Pharmacol.* 130, 1990: 502–11. – 6. Bongers M. L., Hogervorst J. G., Schouten L. J. et al.: Dietary acrylamide intake and the risk of lymphatic malignancies: the Netherlands cohort study on diet and cancer. *Plos One* e38016, 2012. – 7. Boyes W. K., Cooper G. P.: Acrylamide neurotoxicity: effects on far-field somatosensory evoked potentials in rats. *Neurobehavioral Toxicol. Teratol.* 3, 1981: 487–90. – 8. Brismar T., Hildebrand C., Tegner R.: Nodes of Ranvier in acrylamide neuropathy: voltage clamp and electron microscopic analysis of rat sciatic nerve fibres at proximal levels. *Brain Res.* 423, 1987: 135–4. – 9. Butterworth B. E., Eldridge S. R., Sprankle K. S. et al.: Tissue-specific genotoxic effects of acrylamide and acrylonitrile. *Environm. Molec. Mutagenesis* 20, 1992: 148–55. – 10. Collins J. J., Swaen G. M. H., Marsh G. M. et al.: Mortality patterns among workers exposed to acrylamide. *J. Occupat. Med.* 31, 1989: 614–17. – 11. Čihák R., Vontorková M.: Activity of acrylamide in single-, double-, and triple-dose mouse bone marrow micronucleus assays. – 12. Dearfield K. L., Abernathy Ch. O., Ottley M. S. et al.: Acrylamide: its metabolism, developmental and reproductive effects, genotoxicity and carcinogenicity. *Mutation Res.* 195, 1988: 45–77. – 13. DeGrandchamp R. L., Lowndes H. E.: Early degeneration and sprouting of the rat neuromuscular junction following acrylamide administration. *Neuropathol. appl. Neurobiol.* 16, 1990: 239–54. – 14. Dobrowolski P., Huet P., Karlsson P. et al.: Potato fiber protects the small intestinal wall against the toxic influence of acrylamide. *Nutrition* 28, 2012: 428–35. – 15. Duarte-Salles T., von Stedingk H., Granum B. et al.: Dietary acrylamide intake during pregnancy and fetal growth-results from the Norwegian mother and child cohort study. *Environ. Health Perspect.* 121, 2013: 374–9. – 16. Erkekoglu P., Baydar T.: Acrylamide neurotoxicity. *Nutrit. Neurosci.* 17, 2014: 49–57. – 17. Perri G. L., Zareh S., Sbraccia M.: Heterogenous visceral nerve changes in acrylamide intoxication. *Exp. Brain Res.* 87, 1991: 363–70. – 18. Freisling H., Moskal A., Ferrari P. et al.: Dietary acrylamide intake of adults in the European prospective investigation into cancer and nutrition differs greatly according to geographical region. *Eur. J. Nutr.* 52, 2013: 1369–80. – 19. Geryk E., Zudová Z.: Zdravotní riziko při profesionální expozici vinylchloridu. *Pracov. Lék.* 38, 1986: 1–8. – 20. Goffeng L. O., Alvestrand M., Ulvestad B. et al.: Self-reported symptoms and neuropsychological function among tunnel workers previously exposed to acrylamide and N-methylolacrylamide. *Scand. J. Work Environ. Health* 37, 2011: 136–46. – 21. Gold B. G., Halleck M. M.: Axonal degeneration and axonal caliber alteration following combined iminodipropionitrile and acrylamide administration. *J. Neuropathol. exper. Neurol.* 48, 1989: 653–68. – 22. Goldstein B. D., Lowndes H. L.: Spinal cord defect in the peripheral neuropathy resulting from acrylamide. *Neurotoxicol.* 1, 1979: 75–87. – 23. Harry G. J.: Acrylamide-induced alterations in axonal transport. *Molec. Neurobiol.* 6, 1992: 203–16. – 24. Harry G. J., Morell P., Bouldin T. W.: Acrylamide exposure preferentially impairs axonal transport of glycoproteins in myelinated axons. *J. Neurosci. Res.* 31, 1992: 554–60. – 25. Hersch M. I., McLeod J. G., Sullivan C. E.:

Abnormal cough reflex in canine acrylamide neuropathy. *Ann. Neurol.* 26, 1989: 738–45. – 26. Johnson K. A., Gorzinski S. J., Bodner K. M. et al.: Chronic toxicity and oncogenic study on acrylamide incorporated in the drinking water of Fischer 344 rats. *Toxicol. appl. Pharmacol.* 85, 1986: 154–68. – 27. Johnston P. K., Doyle E., Orzel R. A.: Acrylics: a literature review of thermal decomposition products and toxicity. *J. Amer. Col. Toxicol.* 7, 1988: 139–200. – 28. Jolanki R.: Occupational skin diseases from epoxy compounds. *Acta Dermatovenerol., Suppl.* 159: 1–80. – 29. Kopecký J., Linhart I., Stiborová A. et al.: Biotransformace esterů akrylové kyseliny u potkana. *Pracov. Lék.* 37, 1985: 126–29. – 30. Kovařík J., Kuželová M., Šalandová J. et al.: Akrylátů a kyseliny systém. *Českoslov. Neurol. Neurochir.* 50/83, 1987: 95–101. – 31. Kvasničková A.: Akrylamid v potravinách. *Výživa potravin* 65, 2010: 127–9. – 32. Lakshmi D., Gopinath K., Jayanthi G. et al.: Ameliorating effect of fish oil on acrylamide induced oxidative stress and neuronal apoptosis in cerebral cortex. *Neurochem. Res.* 37, 2012: 1859–67. – 33. Lin Y., Lagergren J., Lu Y.: Dietary acrylamide intake and risk of esophageal cancer in a population based case-control study in Sweden. *Int. J. Cancer* 128, 2011: 676–81. – 34. Lineback D. R., Coughlin J. R., Stadler R. H.: Acrylamide in foods: a review of the science and future consideration. *Annu. Rev. Food Sci. Technol.* 3, 2012: 15–35. – 35. LoPachin R. M., Gavin T.: Molecular mechanism of acrylamide neurotoxicity: Lessons learned from organic chemistry. *Environ. Health Perspect.* 120, 2012: 1650–7. – 36. Maier A., Kohrman-Vincent M., Hertzberg R. et al.: Critical review of dose-response options for F344 rat mammary tumors for acrylamide. Additional insights based on mode of action. *Food Chem. Toxicol.* 50, 2012: 1763–75. – 37. Matsuo-ka M., Igisu H., Lin J. et al.: Effects of acrylamide and N, N-methylene-bis-acrylamide on creatine kinase activity. *Brain Res.* 507, 1990: 351–3. – 38. Maurissen J. P., Weiss B., Cox C.: Vibration sensitivity recovery after a second course of acrylamide intoxication. *Fundamental appl. Toxicol.* 15, 1990: 93–8. – 39. Medrano C. J., LoPachin R.: Effects of acrylamide and 2,5-hexanedione on brain mitochondrial respiration. *Neurotoxicol.* 10, 1989: 249–56. – 40. Mojska H., Gielecinska I., Stoš K.: Determination of acrylamide level in commercial baby foods and an assessment of infant dietary exposure. *Food Chem. Toxicol.* 50, 2012: 2722–8. – 41. Moretto A., Sabri M. I.: Progressive deficits in retrograde axon transport precede degeneration of motor axons in acrylamide neuropathy. *Brain Res.* 440, 1988: 18–24. – 42. Neuhäuser A., Schmahl W.: Mutagenic and teratogenic effects of acrylamide in the mammalian spot test. *Mutation Res.* 226, 1989: 157–62. – 43. Obón-Santacana M., Kaaks R., Slimani N. et al.: Dietary intake of acrylamide and endometrial cancer risk in the European prospective investigation into cancer and nutrition cohort. *Br. J. Cancer* 111, 2014: 987–97. – 44. Obón-Santacana M., Slimani N., Lujan-Barroso L. et al.: Dietary intake of acrylamide and pancreatic cancer risk in the European prospective investigation into cancer and nutrition cohort. *Ann. Oncol.* 24, 2013: 2545–51. – 45. Olsen A., Christensen J., Outzen M. et al.: Pre-diagnostic acrylamide exposure and survival after breast cancer among postmenopausal Danish women. *Toxicology* 296, 2012: 67–72. – 46. Pedersen M., von Stedingk H., Botsivali M. et al.: Birth weight, head circumference, and prenatal exposure to acrylamide from maternal diet: the European prospective mother; child study. *Environ. Health Perspect.* 120, 2012: 1739–45. – 47. Pedreschi F., Kaach K., Granby K. et al.: The effect of asparaginase on acrylamide formation in french fries. *Food Chem.* 109, 2011: 386–92. – 48. Pedreschi F., Mariotti M. S., Granby K.: Current issues in dietary acrylamide: formation, mitigation and risk assessment. *J. Sci. Food Agric.* 94, 2014: 9–20. – 49. Pelucchi C., La Vecchia C., Bosetti C. et al.: Exposure to acrylamide and human cancer – a review and meta-analysis of epidemiologic studies. *Ann. Oncol.* 22, 2011: 1487–99. – 50. Pennisi M., Malaguarnera G., Puglisi V. et al.: Neurotoxicity of acrylamide in exposed workers. *Int. J. Environ. Public Health* 10, 2013: 3843–54. – 51. Pruser K. N., Flynn N. E.: Acrylamide in health and disease. *Frontiers Biosci.* S3, 2011: 41–51. – 52. Rosen J., Hellenas K. E.: Analysis of acrylamide in cooked foods by liquid chromatography tandem mass spectrometry. *Analyst* 127, 2002: 880–2. – 53. Russom C. L., Drummond R. A., Hoffman A. D.: Acute toxicity and behavioral effects of acrylates and methacrylates to juvenile Fathead Minnows. *Bull. Environ. Contam. Toxicol.* 41, 1988: 589–96. – 54. Sabri M. I., Dairman W., Fenton M. et al.: Effect of exogenous pyruvate on acrylamide neuropathy in rats. *Brain Res.* 483, 1989: 1–11. – 55. Sakamoto J., Hashimoto K.: Reproductive toxicity of acrylamide and related compounds in mice-effects on fertility and sperm morphology. *Arch. Toxicol.* 59, 1986: 201–5. – 56. Schwartz B. S., Dory R. L., Monroe C. et al.: Olfactory function in chemical workers exposed to acrylate and methacrylate vapors. *Amer. J. Publ. Health* 79, 1989: 613–18. – 57. Sickles D. W.: Neural specificity of acrylamide action upon enzymes associated with oxidative energy-producing pathways. I. Histochemical analysis of NADH-tetrazolium reductase activity. *Neuro Toxicol.* 8, 1987: 623–30. – 58. Sobel W., Bond G. G., Parsons T. W. et al.: Acrylamide cohort mortality study. *Brit. J. Industr. Med.* 43, 1986: 785–8. – 59.

Sobotka P.: EEG nálezy u pracovníků exponovaných akrylátům. Plzeň. lék. Sborn. 80, 2014: 51–5. – 60. Sporel-Özkat R. E., Edwards P. M., Van der HOOp R. G. et al.: An ACTH (49) analogue, Org 2766, improves recovery from acrylamide neuropathy in rats. *Europ. J. Pharmacol.* 186, 1990: 181–7. – 61. Stotzem C. D., Mengs U., Odenthal K. P.: Influence of ganglioside treatment on acrylamide neuropathy in mice. *Drug Res.* 38, 1988: 1563–7. – 62. Sublet V. H., Zenick H., Smith M. K.: Factors associated with reduced fertility and implantation rates in females mated to acrylamide treated rats. *Toxicol.* 55, 1989: 53–7. – 63. Tanii H., Hayashi M., Hashimoto K.: Neurofilament degradation in the nervous system of rats intoxicated with acrylamide, related compounds or 2,5-hexanedione. *Arch. Toxicol.* 62, 1988: 70–5. – 64. Tanii H., Hashimoto K.: In vitro neurotoxicity study with dorsal root ganglia for acrylamide and its derivates. *Toxicol. Letters* 58, 1991: 209–13. – 65. Tarskikh M. M., Klimatskaya L. G., Kolesnikov S. I.: Pathogenesis of neurotoxicity of acrylates acrylonitrile and acrylamide: from cell to organism. *Bull. Exp. Biol. Med.* 155, 2013: 451–3. – 66. Teodor V., Cuciureanu M., Filip C. et al.: Protective effects of selenium on acrylamide toxicity in the liver of the rat. Effects on the oxidative stress. *Rev. Med. Chir. Soc. Med. Nat. Iasi* 115, 2011: 612–8. – 67. Veronesi R., Jones K., Gupta S. et al.: Gene probe for PO messenger RNA used to index acrylamide toxic neuropathy in rats. *Neurotoxicol.* 12, 1991: 715–32. – 68. Veselá H., Šucman E.: Determination of acrylamide in dry foodstuff for dogs and cats. *Acta vet. Brno* 82, 213: 203–8. – 69. Vesper H. W., Sternberg M. R., Frame T. et al.: Among 10 sociodemographic and lifestyle variables, smoking is strongly associated with biomarkers of acrylamide exposure in a representative sample of the U. S. population. *J. Nutr.* 143, 2013: 995S–100S. – 70. Vodička P.: Hygienická charakteristika vybraných derivátů akrylové kyseliny. *Pracov. Léč.* 38, 1986: 463–8. – 71. Walum E.: On the application of cultured neuronal cell lines in neurotoxicological studies: cytotoxicity of acrylamide. *J. Cancer Res. Clin. Oncol.* 115, 1989: 543–9. – 72. Wenzel-Hartung R. P., Brune H., Klimisch H. J.: Dermal oncogenicity study of 2-ethylhexyl acrylate by epicutaneous application in male C3H/HeJ mice. *J. Cancer Res. Clin. Oncol.* 115, 1989: 543–9. – 73. Zajac J., Bojar I., Helbin J. et al.: Dietary acrylamide exposure in chosen population of South Poland. *Ann. Agric. Environ. Med.* 20, 2013: 351–5.

Author's address: P. S. Alej Svobody 1655/76, 323 00 Pilsen, Czech Republic